OPKO Health Inc (OPK) Q2 2026 Earnings Call Highlights: Strong Pharmaceutical Growth
OPKO Health (OPK) reported Q2 2026 revenue of $163.6 million versus $156.8 million a year earlier, with net loss of $8.4 million ($0.01/share). Diagnostics revenue was $74.5 million, including $6.2 million from 4Kscore. Pharmaceutical revenue rose to $89.0 million. OPK said Q3 2026 revenue should be $141–$142 million and full-year 2026 guidance is $560–$585 million.
How this was made
The 30-second read
Why it matters
The newest actionable inputs are the Q3 2026 revenue outlook ($141M-$142M) and the full-year 2026 adjusted revenue guidance ($560M-$585M), alongside segment-level diagnostics softness and 4Kscore CMS approval timing risk.
Market read
Traders can update OPK revenue models and risk assumptions immediately using the provided quarterly and full-year guidance, while monitoring CMS confirmation timing for 4Kscore expansion.
What to watch
The article notes higher costs in employee benefits and professional fees, and 4Kscore maturation delays; traders may need to watch margin trajectory and whether ModeX and CAR-T enrollment timelines slip.
Background
This is an earnings call highlights recap for OPKO Health covering Q2 2026 financials, business segment performance, and forward revenue guidance.
Ticker impact
OPKO reported Q2 2026 results and updated 2026 revenue guidance to $560M-$585M, plus a Q3 outlook of $141M-$142M.
Likely positive bias for OPK as traders anchor on the raised/adjusted full-year range and Q3 revenue outlook, partially offset by diagnostics softness and 4Kscore CMS uncertainty.
The article provides multiple concrete financial datapoints (consolidated revenue, net loss improvement, Q3 outlook, full-year guidance) and operational notes (ModeX progress, 4Kscore Medicare/CMS confirmations pending) that can drive earnings-model revisions and risk premium changes.
Market effects
Biopharma and diagnostics investors may reprice near-term revenue durability and payer-regulatory execution risk for companion diagnostics tied to CMS.
No clear regional spillover beyond US small/mid-cap biotech sentiment.
Limited global read-through; primarily US payer and clinical-development execution.
Counterpoint
The diagnostics decline and 4Kscore CMS dependency could mean the guidance relies on slower-than-expected payer expansion, making the upside more fragile than the headline growth suggests.
Key entities
- companyOPKO Health Inc
Subject of the earnings call highlights, including Q2 results and updated 2026 revenue guidance.
